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Abstract
Chronic liver damage leads to pathological accumulation of ECM proteins (liver fibrosis).
Comprehensive characterization of the human ECMmolecular composition is essential for
gaining insights into the mechanisms of liver disease. To date, studies of ECM remodeling
in human liver diseases have been hampered by the unavailability of purified ECM. Here,
we developed a decellularization method to purify ECM scaffolds from human liver tissues.
Histological and electron microscopy analyses demonstrated that the ECM scaffolds,
devoid of plasma and cellular components, preserved the three-dimensional ECM structure
and zonal distribution of ECM components. This method has been then applied on 57 liver
biopsies of HCV-infected patients at different stages of liver fibrosis according to METAVIR
classification. Label-free nLC-MS/MS proteomics and computation biology were performed
to analyze the ECMmolecular composition in liver fibrosis progression, thus unveiling pro-
tein expression signatures specific for the HCV-related liver fibrotic stages. In particular, the
ECMmolecular composition of liver fibrosis was found to involve dynamic changes in matrix
stiffness, flexibility and density related to the dysregulation of predominant collagen, elastic
fibers and minor components with both structural and signaling properties. This study con-
tributes to the understanding of the molecular bases underlying ECM remodeling in liver
fibrosis and suggests new molecular targets for fibrolytic strategies.
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Introduction
The extracellular matrix (ECM) is a critical component of the human liver microenvironment.
Forming a fibrous scaffold, the ECM provides a surface for cell adhesion, space for cell growth
and migration, and acts as reservoir for signaling molecules [1]. Moreover, several ECM com-
ponents, such as collagen, fibronectin and laminin, are responsible also for promoting the
expression of liver-specific functions and cell differentiation [2]. Furthermore, the local stiff-
ness of the liver ECM is an important mechanical effector of cellular behavior and tissue forma-
tion. Particularly, cellular responses to mechanical signals of liver ECM include differentiation,
migration, proliferation, and alterations in cell—cell and cell—matrix adhesion [3].
Wound repair is a dynamic process in which the liver ECM composition and stiffness
become critically important. In fact, continuous ECM remodeling during chronic liver injuries
leads to an altered and excessive accumulation of extracellular proteins, proteoglycans and car-
bohydrates, thus leading to fibrosis, which is responsible for the morbidity and mortality asso-
ciated with liver failure [4]. Therefore, the identification and quantitation of the ECM
components, spatial and temporal dynamics of ECMmolecules, and interactions underpinning
ECM proteins networks represent the key steps towards understanding the role of ECM in tis-
sue remodeling in liver disease. However, the study of human liver ECM components is gener-
ally hampered by the difficulty of isolating the matrix scaffold from hepatic cells.
Liver decellularization by portal perfusion is an attractive technique for the whole scaffold
isolation. In animal models, this approach allows for isolating the ECM, retaining the architec-
ture of the original tissue and permitting applications, both in large-scale investigations of
components and in tissue engineering for regenerative medicine [5]. However, human liver
decellularization by portal perfusion is only applicable in explanted diseased organs, thus limit-
ing any study at the onset and progression of liver fibrosis.
To date, the proteomic attempts to characterize the components of human liver ECM were
performed by analyzing the secretion of ECM producing cells in vitro or by protein enrichment
from homogenized liver tissues [6, 7]. However, cell-derived ECM is a far cry from reflecting
the native liver scaffold and does not allow for any study on the ECM dynamics in liver fibrosis
progression. On the contrary, studies based on the ECM protein enrichment from homoge-
nized liver tissues do not allow for reducing or eliminating the contribution of cellular compo-
nents, hence, resulting in overestimations of quantitative data acquired by proteomic
approaches. Thus, deciphering the human ECMmolecular composition from isolated liver
scaffolds still represents an important scientific challenge.
Here, we designed a biochemical-based strategy for the isolation of human hepatic ECM scaf-
folds that is already effective on liver biopsy specimens. This decellularization approach allows
for preserving the “bonafide” native matrix structure and, net of cell membrane ECM-interact-
ing proteins (e.g. integrins, ADAMTS, MT-MMPs), the ECMmolecular composition. Then, we
made use of the isolated liver scaffolds to delineate and compare, by a label-free quantitative
mass-spectrometry-based approach, the proteome changes of ECM components in the different
stages of liver fibrosis in HCV-infected patients. This investigation first discloses the ECM
molecular composition that characterizes the transition frommoderate to severe fibrosis, and
defines a specific ECM signature for the bridging fibrosis with nodular regeneration (cirrhosis).
Materials and Methods
Ethics statements and samples
The collection and use of residual diagnostic liver biopsy samples for research purposes has
been approved by the ethical committee of the “L. Spallanzani”National institute for Infectious
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Abbreviations: ECM, extracellular matrix; nLC-MS,
nano liquid chromatography-mass spectrometry;
SEM, Scanning Electron Microscopy; NLT, normal
liver tissue; DLT, decellularized liver tissue; PT, portal
tracts; THV, terminal hepatic veins; ADAMTS, a
disintegrin and metalloproteinase with
thrombospondin motifs; MT-MMPs, membrane-bound
MMPs (MT-MMPs).
Diseases, IRCCS, Rome, Italy. The patients accepted to participate in the study by signing an
informed consent. All the samples have been completely anonymized, leaving only clinical
information relevant for study purposes.
The collection and use of murine liver samples has been approved University of Palermo
Animal Care Committee. Murine liver specimens were harvested from 6-week-old mice
(Charles River Laboratories), maintained in accordance with the institutional guidelines of the
University of Palermo Animal Care Committee. All mice were housed under controlled condi-
tions for temperature and humidity in a specific pathogen free facility, using a 12 h light/dark
cycle and ad libitum access to water and food.
The experimental procedures have been communicated to the Ministry of Health in accor-
dance with the ministerial directive at the time of the experiments: legislative decree 116/92,
annex 4 to the circular of the Ministry of Health n. 8 of 1994. No suffering was inflicted on the
animals before euthanasia. Mice welfare was evaluated by checklist for the determination of
endpoints: appearance, natural behavior, hydration status, clinical signs, provoked behavior,
grimace scale and body conditioning scoring. No animals became severely ill or died prior to
the experimental endpoint. Euthanasia in mice was performed by carbon dioxide asphyxiation.
Liver tissue decellularization
Plasma proteins removal from liver tissues was performed by overnight shaking (600 RPM) in
Step 1 Washing Buffer (0,5 M NaCl, 10 mM Tris Base pH 7.5, 1X protease inhibitor) at 4°C.
After centrifugation at 13000 RPM for 1 minute, the supernatants (plasma proteins) were
stored at −80°C. Pellets were washed twice with Step 2 Decellularization Buffer (DB) (1% SDS
in PBS, 1X protease inhibitor) and incubated overnight in DB at room temperature, shaking at
800 RPM. On the next day, the supernatants were removed and stored at −80°C and fresh DB
was added to the tissues. This process was repeated until the tissues were completely decellular-
ized (two to three days for bigger specimens). All supernatants from the Step 2 process (con-
taining mainly cellular proteins) were pooled in one tube. Decellularized tissues were washed
twice with deionized water and incubated with 80% acetone for 90 minutes to remove residual
SDS. After centrifugation at 12000 RPM for 15 min at 4°C the supernatants were discarded and
the ECM scaffold samples were washed twice with PBS.
Histological analyses
Each human biopsy sample was evaluated histologically according to the METAVIR grading
system for disease stage and grade of necroinflammatory activity. Tissue specimens were fixed
in 10% buffered formalin and embedded in paraffin. 4μm-thick slices were cut and stained
with hematoxylin and eosin (H&E), Masson’s trichrome and silver impregnation. Immunos-
taining was performed on Benchmark XT system (Ventana, Tucson, AZ, USA). Fibronectin
(BD Biosciences, Erembodegem, Belgium), albumin and E-cadherin (Abcam, Cambridge,
UK) antibodies were used at dilution of 1:200. Liver lobes from mouse explants, after decellu-
larization, were stained with DAPI over night and observed at inverted microscope Nikon
Eclipse Ti.
Scanning Electron Microscopy, Western blotting, Mass spectrometry
and data analysis
See S1 File for more detail.
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Results
Liver ECM scaffold isolation by tissue decellularization
ECM isolation by immersion and agitation in decellularization agents has been applied for a
wide variety of tissue specimens, including dermis, skeletal muscles, peripheral nerves and
heart valves [8]. However, the particular hepatic tissue cellularity, density and thickness have
been critical determinants that hampered the translation of this approach to liver biopsy speci-
mens [8].
We achieved human liver ECM scaffold isolation by establishing a two-step protocol that
requires a liver biopsy immersed in differential buffers and then subjected to gentle and con-
tinuous agitation (Fig 1A). In the first step, the blood was flushed out from the liver biopsy by
means of a washing buffer, thus turning the color of the tissue to yellowish-brown in 24 hours
(Fig 1B, upper panels). In the second step, after 48 hours of decellularization buffer, a translu-
cent acellular scaffold, which retained the gross shape of a liver biopsy, was generated (Fig 1B,
upper panels). Notably, similar results were obtained applying this protocol to mouse liver
lobes, thus indicating that the effectiveness of the method is not limited to the biopsy speci-
mens size (Fig 1B, lower panels). Western blotting analysis provided evidence of the successful
isolation of liver bioscaffold highly enriched for ECM components (Fig 1C). Mass spectrome-
try analysis highlighted that collagens represented more than 60% of the human liver ECM
scaffold molecules, while non-collagenous proteins and proteoglycans contributed to 28,81%
and 6,35%, respectively. (Fig 1D and S1 Table). As expected, the analysis of total collagen
components showed a predominant abundance of fibrillar collagen type I (COL1A1 and
COL1A2) (S1 Fig). Interestingly, five of the collagen proteins (COL2A1, COL21A1,
COL23A1, COL5A3 and COL26A1) were found in the matrix of human adult liver. To the
best of our knowledge, this study represents the first evidence of these proteins in the matrix
of human adult liver, thus further highlighting the efficacy of the ECM scaffold isolation
procedure.
Characterization of the decellularized liver ECM scaffold
To investigate the effects of decellularization protocol on the extracellular matrix network, his-
tological investigations were performed. Hematoxylin/eosin and trichrome stain highlighted
that no nuclei or cytoplasmic staining were observed in decellularized human liver tissue (Fig
2A, left and middle panel respectively), as well as the immunostaining for fibronectin showed
that the isolated liver ECM scaffold retained the typical network of web-like structures (Fig 2A,
right panel). Moreover, the portal tracts and terminal veins connective structures were pre-
served, suggesting that the microvascular scaffold remained intact (Fig 2A). Notably, the same
results were observed when the decellularization process was applied to larger portions of liver
tissue (i.e. murine hepatic lobe); S2 Fig shows as the scaffold of the vascular tree is clearly
apparent, thus suggesting that the larger circulation system of vessels was also preserved.
It is well established that normal liver parenchyma contained only few collagen fibers, while
these are more abundant in the portal tract [9]. By means of scanning electron microscopy
(SEM), we further investigated if our decellularization approach was able to retain the different
zonation of collagen structures. As shown in Fig 2B, we found that the density of collagen fibers
was higher in the portal tracts than in the parenchymal area, which instead appears as a non-
fibrillar network structure.
Taken together, these data demonstrated that this decellularization method generates
hepatic scaffolds that preserve the main structural properties of human ECM, thus filling a
void in the availability of proper experimental tools for studying human liver biology.
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Fig 1. Decellularization of liver tissues. (A) Schematic representation of the two-step decellularization protocol; for details see Methods section.
(B) Representative images of human and murine liver tissues during the decellularization process at the indicated times. Scale bars: 5 mm. (C) Western
blot analysis of supernatants for the indicated proteins. For each gel lane, 10 μg of protein sample were loaded; albumin was used as plasma and cellular
protein markers; calnexin was used as a cellular protein marker. The lack of calnexin in supernatant 3 indicates the removal of plasma and cellular
proteins from the scaffold. One representative experiment out of three is shown. (D) Percentage of ECM category components of human liver scaffold.
The pie chart displays the results of one human decellularized liver biopsy with low fibrosis processed through the proteomics workflow. For each
identified protein, protein abundance was calculated using the frequency of tandem mass spectra assigned to that protein.
doi:10.1371/journal.pone.0151736.g001
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Fig 2. Histological and ultrastructural analysis of decellularized human liver ECM scaffold. (A) Comparison of human normal liver (NLT) and
decellularized liver (DLT) tissues for the indicated staining. Portal tracts (PT) and terminal hepatic veins (THV) are indicated. Scale bars: 100 μm. (B) SEM
images of the extracellular matrix in the portal tract and parenchyma. Collagen fibers (white arrows) are indicated. Scale bars: 1 μm.
doi:10.1371/journal.pone.0151736.g002
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Molecular remodeling of human ECM in HCV-induced liver fibrosis
Fifty-seven decellularized liver biopsies were processed to evaluate the molecular ECM changes
occurring during fibrosis progression in HCV-infected patients. By histological diagnosis, sam-
ples of 1 cm in length were classified according to the Metavir score as follows: 14 in portal
fibrosis (F1); 19 in moderate fibrosis (F2); 14 in severe fibrosis (F3); and 10 in bridging fibrosis
(F4) (S2 Table). Liver samples were then individually decellularized, and the produced ECM
liver scaffolds underwent trypsin digestion. The obtained peptides were pooled according to
fibrotic stage and then subjected to proteomic analysis.
By means of the nLC-MS-based label free proteomics approach, we quantified forty-seven
ECM-associated proteins to be differentially expressed in the evolution of liver fibrosis. Firstly,
we analyzed the absolute abundance of the major structural ECM components. As expected,
liver fibrosis evolution from F1 to F3 stages requires a progressive accumulation of fibrillar col-
lagen (type I and III) and elastin (Fig 3 and S2 Table). Interestingly, the achievement of liver
cirrhosis (F4) involves a massive accumulation of elastic fiber (i.e. elastin overexpression in Fig
3) concomitantly with a moderate decrease of type I and III collagens. These data suggest that
the liver fibrosis progression modifies the liver stiffness by a combination of predominant col-
lagen and elastic fibers.
Then, to clarify the specific contribution of each ECM component in liver fibrosis progres-
sion, a relative abundance analysis was performed by comparing the protein expression profiles
of F2, F3 and F4 stages in respect to the minimal stage (F1) (Fig 4 and S2 Table). By heat map
analysis (Matrix2png, version 1.2.2), we unveiled that fibrotic stage F2 involves a slight increase
for the most predominant collagens (type I and III) (Fig 4). Among the lower abundance colla-
gen chains, COL10A1, COL14A1, COL16A1 were down-regulated, while COL12A1 was found
up-regulated. Surprisingly, a general down-regulation of non-collagenous proteins, such as
elastin (ELN), tenascin (TNC), laminin gamma-1 (LAMC1), latent-transforming growth factor
Fig 3. Dynamic changes of the major ECM structural components in HCV-induced liver fibrosis
progression. Protein abundance was calculated using the LTQ intensity assigned to that protein. LTQ
intensity was determined as average of three independent experiments. For details see S2 Table.
doi:10.1371/journal.pone.0151736.g003
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beta-binding proteins 1 (LTBP1) and 4 (LTBP4) was observed. Among the proteoglycans, pro-
teoglycan 4 (PRG4) was down-regulated; on the contrary, lumican (LUM) expression was
found increased. Interestingly, metalloproteinase inhibitor 3 (TIMP3), known to irreversibly
inactivate the collagenases, and to be a critical regulator of hepatic inflammation, cell death
and survival [10, 11], was found underexpressed (ratio F2/F1 = 0,36), thus suggesting a tissue
response to the pathological accumulation of ECM.
Fig 4. Liver ECM proteome profiles in HCV-induced liver fibrosis progression. Abundance ratios F2/F1,
F3/F1 and F4/F1 were calculated and analyzed by heat map analysis. Each vertical column represents an
individual abundance ratio and each horizontal row an individual protein. Protein abundance ratios were
colored according to fold changes (yellow Log10 ratios: down-regulations; blue Log10 ratios: up-regulations),
and the color scale indicates the magnitude of expression changes. Black squares indicate no change in
protein abundance. Gray squares indicate missing data.
doi:10.1371/journal.pone.0151736.g004
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Severe fibrosis (F3) requires the overexpression of most of the ECM protein components
(Fig 4). As expected, type I and III collagen levels and the most abundant non-collagenous pro-
teins (ELN, fibulin-3 (EFEMP1), fibulin-5 (FBLN5), emilin-1) were found up-regulated. These
data are consistent with the strong increase in TIMP3 expression (ratio F3/F1 = 4,59), thus
indicating the inhibition of fibrolytic processes. Interestingly, protein abundances of
COL10A1, COL12A1, COL16A1, LTBP1 e LTBP4 showed opposite trends in respect to those
observed in the F2 stage. With the exception of biglycan (BGN) and perlecan (HSPG2), the
expression levels of proteoglycan components (LUM, PRG2, PRG4) were found increased two-
to three-fold.
Achievement of bridging fibrosis (F4) with nodule formation (cirrhosis) is characterized by
a protein expression pattern that differs significantly from the F3 stage. As expected, the
expression levels of ELN, FBLN5, microfibril-associated glycoprotein 4 (MFAP4) and vitronec-
tin (VTN) were detected with a minimum three-fold increase. On the contrary, several non-
collagenous proteins such as fibrinogen beta chain (FGB), LTBP4, microfibrillar-associated
protein 2 (MFAP4), tenascin-X (TNXB) were found underexpressed, with expression levels 5
times lower. Predominant collagen profile is characterized by a slight transition from the type
I, III and V fibril collagen to the non-fibril, network-forming type VI. Notably, in respect to
stage F3, the lower abundance collagen chains expression showed COL14A1 in overexpression
and COL16A1 and COL18A1 strongly decreased. Proteoglycan expression revealed the up-reg-
ulation of LUM and PRG2, while the abundance levels of BGN, that showed a gradual decrease
during fibrosis progression, were found underexpressed up to 12 times in cirrhosis. Interest-
ingly, the transition from stage F3 to F4 involves the down-regulation of all the identified
ECM-affiliated proteins and ECM regulators. Finally, angiopoietin-related protein 6
(ANGPTL6), a secreted protein known to be involved in the wound healing process by pro-
moting remodeling and regeneration of tissues [12], was found strongly up-regulated.
Finally, in order to focus on ECM proteins that may represent a molecular signature of
transition from one stage to another the protein ratios of F2/F1, F3/F2 and F4/F3 were calcu-
lated by the ratio of the ratios and the resulting values converted in fold changes (S3 Table).
Then, proteins with a higher fold-change (>2) and lower fold-change (<2) abundances were
considered and are represented in Fig 5. Interestingly, we found that most of the dysregulated
proteins were the so far undescribed minor components of the ECM (listed in S3 Table and
Fig 4), thus indicating that the transitions among the HCV-related fibrous stages involve
fiber formation and accumulation, as well as dynamic changes in molecules with signaling
properties.
Discussion
Obtaining a comprehensive description of the ECMmolecular composition in human liver
health and disease has so far been hampered by the difficulty to isolate decellularized hepatic
ECM scaffolds. This study first describes the isolation of liver tissue-derived ECM scaffolds
that preserve the “bona fide” three-dimensional architecture and native matrix composition.
Then, once the suitability of the decellularization protocol was verified, we made use of it to
attempt to make a comprehensive study of human ECM dynamic changes in the course of
HCV-induced liver fibrosis. New fibrotic stage-specific molecular signatures have been
unveiled, in particular, highlighting the involvement of the previously described minor compo-
nents of the ECM.
To date, liver ECM scaffold isolation is based on portal vein perfusion of whole animal
organs [5, 13], while decellularization of specimens (i.e. biopsy and surgical samples) have so
far been, hampered by hepatic tissue cellularity, density and thickness. To circumvent this
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issue, biochemical and mechanical conditions to sequentially remove the circulating and cellu-
lar fractions from the liver tissue were developed. The resulting hepatic matrix shows translu-
cent scaffolds, zonal distribution of ECM components, and suggests intact micro- and
macrovascular trees similar to those obtained by perfusion-based whole organ decellulariza-
tion. In light of this, the proposed protocol, that is independent from the perfusion, may justify
efforts to scale up the technique for applications in humans.
The development of liver fibrosis, particularly cirrhosis, is associated with significant mor-
bidity and mortality. At present, since the only curative treatment for end-stage cirrhosis is
transplantation, there is a considerable need for therapeutic strategies to counteract fibrosis
progression. A prerequisite for developing such strategies is having ample knowledge of ECM-
associated molecules. This study, performed directly on purified hepatic ECM scaffolds,
allowed for a comprehensive and specific analysis of the liver ECM components. The identifi-
cation of COL2A1, COL21A1, COL23A1, COL5A3 and COL26A1 as new molecular compo-
nents of the liver ECM confirms this.
With respect to the final and most ambitious goal guiding our research, to compare the
ECM proteome changes occurring in all the fibrotic stages of HCV-infected patients, overall,
the obtained data i) are in good agreement with the changes observed by recent reports, ii)
unveil new fibrotic stage-specific molecular signatures, iii) underline the molecular bases of the
METAVIR score system, thus confirming its efficacy.
In fact, while fibrotic stage-specific changes of several ECM components (among them
LUM, FBLN5, COL14A1, MFAP4, VTN, COL6A1) are in line with recent reports [14–16],
new data highlight the dysregulation of non-fibrillar collagens, proteoglycans and additional
minor components of the liver ECM.
Fig 5. Schema summarizing the ECM protein components that are differentially regulated in the transitions among the fibrotic stages. Data are
shown as follows: blue for up-regulated proteins, yellow for down-regulated proteins; the position in the graph indicates the transition between two fibrotic
stages in which the protein was found differentially regulated.
doi:10.1371/journal.pone.0151736.g005
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(F2)
With the exception of a slight increase for collagen types I and III, the transition from portal to
moderate fibrosis is characterized more by ECM remodeling than by its increase. In particular,
a general down-regulation of the FACIT (fibril-associated with interrupted triple helics) colla-
gens (COL14A1 and COL16A1) was observed. Since FACIT collagens, associating with mature
portal fibrils of collagen I and III, confer flexibility to them [17], our data suggest that the ECM
in moderate fibrosis acquires a dense structure. The low flexibility of the portal ECM in moder-
ate fibrosis is further suggested by the down-regulation of PRG4, also called lubricin, known
for its lubricating and protective actions in many connective tissues, including the liver [18].
(F3)
The main efforts to manage HCV-related liver disease are concentrated in developing anti-
fibrotic strategies to counteract the transition from moderate to severe fibrosis. In fact, as fibro-
sis progresses to the F3 stage, portal to central gradients are lost, septa become continuous, and
resident cells in the space of Disse dedifferentiate [4]. Here, we observed that all of the most
abundant ECM components (i.e. fibrillar collagens, proteoglycans and fibronectin) were up-
regulated, thus confirming that the hepatic ECM acquires stiffness.
Massive ECM accumulation is normally induced by the ECM-resident profibrogenic mole-
cules. The transforming growth factor-b (TGF-b) is one of the major profibrogenic molecules:
its overexpression has been demonstrated to induce severe liver fibrosis [19]. TGF-b is secreted
to the extracellular space in the liver as a latent complex bound to latent TGF-b-binding pro-
teins (LTBPs) [20]. LTBP1 was previously found to be up-regulated in liver tissue from patients
with chronic hepatitis C [21].
Notably, large amounts of two members of LTBPs (LTBP1 and LTBP4) were found depos-
ited in the ECM of patients with stage F3 fibrosis. In light of this, it is conceivable that LTBP1-
and 4-mediated deposition, and targeting of latent, activatable TGF-beta into ECMmay exert a
pivotal role in F2-F3 transition. We believe that the involvement of these two cytokines in
severe fibrosis needs to be addressed in further studies.
(F4)
The entire liver architecture is lost when fibrosis advances to cirrhosis. This is generated by the
formation of massive dense fibrous septa that delineate hepatocellular nodules [22]. This study
unveiled that the ECM composition of the cirrhotic liver shows a characteristic molecular sig-
nature for the non-fibrillar collagenous components. In particular, our data support the
hypothesis that cirrhotic-specific ECM remodeling may be mediated by the overexpression of
proteins involved in network-forming collagen and elastic fiber assembly. COL6A1 is the main
component of the heterotrimeric collagen VI, which forms branching filamentous networks
[23]. Once in overexpression, it anchors structures, such as the blood vessels, to fibrillar colla-
gens, thus distorting the tissue architecture [24]. The elastic fibers are formed from elastin and
many elastic microfibril proteins (consisting of numerous proteins such as microfibrillar-asso-
ciated glycoproteins, fibrillins, fibullins and elastin receptors) [25]. Increased amounts of elastic
fibers have been associated to the pathological remodeling of tissue [26]. Moreover, fibrous
septa particularly rich in cross-linked elastic fibers are known to be more resistant to matrix
metalloproteinases (MMPs)-mediated degradation, thus contributing to fibrosis irreversibility
[27]. Here, a massive accumulation of ELN, FBLN5 and MFAP4 in the ECM of cirrhotic
patients was observed. Therefore, these proteins might represent multiple targets to develop
therapeutic strategies to facilitate liver cirrhosis reversion. Fig 5 recapitulates the HCV-associ-
ated liver fibrotic molecular stage-specific hallmarks observed here, and notably, emphasizes
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the match between the METAVIR-based histological evaluation and the molecular dynamic
changes observed.
In conclusion, this study contributes to the knowledge of human ECM composition in liver
fibrosis progression. However, we believe that this should be considered as a starting point, as
many issues on the ECM structure of fibrotic liver still remain to be addressed. What is the
intra- and intermolecular cross-linking profile? What cross-links have a role in inhibiting ECM
degradation? What is the cellular origin of the described proteins? What kind of post-transcrip-
tional and post-translational regulations occur in the pathological deposition of the ECMmole-
cules? We believe that the presented data will support future studies to address these issues.
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